Successful management of treatment resistant nail psoriasis with tildrakizumab

Abstract Nail psoriasis significantly impacts quality of life and is notoriously difficult to treat. Tildrakizumab, an IL‐23 inhibitor, has shown significant clinical improvement in the treatment of moderate‐to‐severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off‐label tildrakizumab. The dosing regimen utilised was consistent with that used to treat chronic plaque psoriasis, with 100 mg subcutaneously at Day 0 and Week 4, and maintenance dosing of 100 mg every 12 weeks thereafter. Significant improvement at 6 and 12 months, as per the modified Nail Psoriasis Severity Index (mNAPSI) and Dermatology Life Quality Index (DLQI), was seen. There have been no tildrakizumab related side effects observed to date. Tildrakizumab appears to be an effective option in managing treatment resistant nail psoriasis.